CAR-T Therapy Shows Promise for Stiff Person Syndrome
Adults with stiff person syndrome may find early hope in a small trial where two patients regained lost everyday function.
Updated on Nov. 9, 2026 in Stroke

A clinical trial led by Mayo Clinic in Rochester found that CAR-T cell therapy produced dramatic improvements in people with stiff person syndrome, a rare, progressively worsening neurological disorder. Two trial patients regained everyday function lost to the condition, according to results published in JAMA Neurology.
Why it matters
Stiff person syndrome affects an estimated 8,000 people worldwide, twice as many women as men, and standard treatments can stop controlling symptoms over time. The findings suggest an immune-directed approach may be worth testing further for a condition that has few options once symptoms progress.
The results come from a small clinical trial led by Mayo Clinic, with two patients showing regained daily function. Because the sample is this limited, the findings are preliminary and should not be read as proof the therapy works for everyone with the condition.
The players
Mayo Clinic
Mayo Clinic is a major academic medical center based in Rochester, Minnesota, known for research across neurology and immunotherapy, and it led this trial.
JAMA Neurology
JAMA Neurology is a peer-reviewed medical journal published by the American Medical Association that covers research on neurological disorders.
Celine Dion
Celine Dion is a singer who publicly revealed in December 2022 that she had been diagnosed with stiff person syndrome, raising awareness of the rare condition.
The details
CAR-T cell therapy works by teaching the body's immune system to recognize and attack disease-causing cells. Patients in the trial received a one-off infusion of the therapy. Stiff person syndrome is thought to be an autoimmune condition, meaning the immune system mistakenly attacks healthy cells, and CAR-T is being tested for its ability to reset that misdirected immune activity.
Timeline
Shari St Germain was diagnosed with stiff person syndrome in 2021.
Celine Dion publicly announced her diagnosis in December 2022.
Standard treatments stopped controlling St Germain's symptoms in 2024.
The trial results were published in JAMA Neurology on November 9, 2026.
Health Landscape
CAR-T therapy is already approved for certain cancers, and this trial extends its use into an autoimmune neurological disorder. Stiff person syndrome currently has limited treatment options that can lose effectiveness over time, so an immune-targeted approach represents a new direction in managing the condition.
If you or someone you know has unexplained muscle stiffness or spasms that are worsening over time, it is worth raising with a neurologist, who can evaluate the symptoms. This research is early, so it does not change current care, but it may be worth asking a specialist about clinical trial options if standard treatments are no longer controlling symptoms.
The takeaway
Immune-targeted therapies are beginning to be tested for autoimmune neurological conditions that have few options. If standard treatments have stopped controlling symptoms, ask a neurologist whether clinical trials for emerging therapies are an appropriate conversation to have.
Further reading
Explore more on this area in our Stroke coverage for the latest developments in neurological care.





